DIANEAL PD-1 W/ DEXTROSE 3.5% IN PLASTIC CONTAINER
Clinical safety rating: caution
Comprehensive clinical and safety monograph for DIANEAL PD-1 W/ DEXTROSE 3.5% IN PLASTIC CONTAINER (DIANEAL PD-1 W/ DEXTROSE 3.5% IN PLASTIC CONTAINER).
Dianeal PD-1 with dextrose 3.5% is a peritoneal dialysis solution that uses dextrose as an osmotic agent to create an osmotic gradient across the peritoneal membrane, facilitating the removal of waste products (urea, creatinine) and excess fluid from the blood into the dialysate.
| Metabolism | Dextrose is metabolized via glycolysis and the Krebs cycle; approximately 70-80% of dextrose absorbed from the peritoneal cavity is metabolized systemically. |
| Excretion | Renal (virtually 100% of absorbed dextrose and metabolites); peritoneal dialysis removes glucose and metabolic byproducts, but significant elimination occurs via transperitoneal absorption into systemic circulation followed by renal excretion (in patients with residual renal function). In anuric patients, glucose is metabolized and eliminated as CO2 and water, with minimal direct excretion. |
| Half-life | Glucose: 1.5–2 hours (intraperitoneal administration leading to systemic absorption); clinical context: prolonged in renal impairment due to decreased clearance of metabolic products, but glucose itself is rapidly metabolized. |
| Protein binding | Minimal (<10%) for glucose; no significant binding to plasma proteins. |
| Volume of Distribution | 0.15–0.25 L/kg for glucose (approximates extracellular fluid volume); clinically, distributes primarily in extracellular water after absorption from peritoneal cavity. |
| Bioavailability | Intraperitoneal: approximately 70–80% of administered glucose is absorbed systemically over a 4–6 hour dwell; absorption is incomplete due to metabolism within peritoneal cavity and drainage. |
| Onset of Action | Intraperitoneal: 30–60 minutes for ultrafiltration and solute removal; maximal effect on glucose absorption and osmotic gradient achieved within 2–4 hours. |
| Duration of Action | Intraperitoneal: 4–6 hours for dwell time (standard exchange); clinical note: longer dwells (e.g., 8–12 hours overnight) result in increased glucose absorption and reduced ultrafiltration efficiency. |
2-3 L intraperitoneally, dwell time 4-6 hours, 4-5 exchanges per day
| Dosage form | SOLUTION |
| Renal impairment | No dose adjustment required as drug is administered directly into peritoneal cavity |
| Liver impairment | No dose adjustment required |
| Pediatric use | 30-40 mL/kg intraperitoneally per exchange, dose adjusted to achieve target ultrafiltration and solute clearance |
| Geriatric use | Same as adult dosing, monitor fluid and electrolyte balance closely |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for DIANEAL PD-1 W/ DEXTROSE 3.5% IN PLASTIC CONTAINER (DIANEAL PD-1 W/ DEXTROSE 3.5% IN PLASTIC CONTAINER).
| Breastfeeding | Dextrose is endogenous glucose; peritoneal absorption is minimal. M/P ratio unknown. Considered compatible with breastfeeding; monitor infant for glucose tolerance if high doses used. |
| Teratogenic Risk | No evidence of teratogenicity in animal studies; intraperitoneal dextrose solutions are considered low risk. However, maternal acidosis or electrolyte disturbances could indirectly affect the fetus. Caution is advised in the first trimester due to lack of human data. |
■ FDA Black Box Warning
Not FDA-approved for intravenous use; do not administer intravenously.
| Serious Effects |
["Pre-existing severe hyperglycemia or diabetic complications unresponsive to control","Severe abdominal wall defects or recent abdominal surgery","Peritoneal adhesions or fibrosis compromising dialysate flow","Documented loss of peritoneal function or membrane failure","Hypersensitivity to any component"]
| Precautions | ["Monitor for peritonitis, catheter infections, and exit site infections","Risk of electrolyte disturbances, including hypernatremia, hypokalemia, hypocalcemia, and hyperglycemia","Dehydration/hypovolemia due to excessive fluid removal","Respiratory compromise due to increased intra-abdominal pressure","Encapsulating peritoneal sclerosis (rare)"] |
| Food/Dietary | No direct food interactions with Dianeal PD-1 itself. However, as a peritoneal dialysis solution, it provides dextrose which may increase blood glucose; diabetic patients should monitor glucose closely. Encourage a renal diet: low sodium, low potassium, low phosphorus, and controlled protein intake. Avoid excessive fluid intake; typically 500-1000 mL plus urine output per day. |
Loading safety data…
| Fetal Monitoring |
| Monitor maternal serum electrolytes (especially potassium and calcium), glucose, acid-base status, and renal function. Fetal monitoring for growth and well-being if significant maternal metabolic disturbances occur. |
| Fertility Effects | No known direct effect on fertility. May impact fertility if underlying renal dysfunction or metabolic issues are present. |
| Clinical Pearls | Use only 1.5%, 2.5%, or 4.25% dextrose solutions; 3.5% is not available in Dianeal PD-1. Adjust fill volume based on patient size and tolerance; typical initial fill volume for adults is 2 liters. Monitor for outflow obstruction and peritonitis. Warm solution to body temperature before use to reduce discomfort. Inspect bag for leaks and solution clarity before administration. |
| Patient Advice | Wash hands thoroughly before handling the dialysis system. · Check the solution for cloudiness, particles, or leaks before use. · Warm the solution to body temperature (not microwave) before infusion. · Record your weight daily and report any gain of more than 2 pounds over 2 days. · Monitor for signs of infection like redness, tenderness, or drainage at the catheter exit site. · Adhere to strict aseptic technique during exchanges to prevent peritonitis. · Report abdominal pain, fever, or change in effluent color/cloudiness immediately. · Follow a low-sodium, low-potassium diet as instructed by your renal dietitian. |